Palantir and Sadiq Khan drop legal battle over Met contract

Palantir and London’s Mayor’s Office for Policing and Crime withdrew allegations against each other, avoiding a High Court trial over the blocked two-year, £50m Metropolitan Police technology contract; neither side admitted liability, paid damages, or agreed to cover the other’s legal costs. A new procurement process is under way, and Mopac says it will treat Palantir fairly and equally if it bids, but it is not bound to select the company. Palantir also faces a campaign to replace it on its £330m NHS medical data contract.

Analysis

The settlement removes a litigation overhang, not the underlying procurement or political risk. The key distinction is that Mopac’s statement narrows the dispute to process, but does not commit it to award Palantir the contract; the re-tender remains the near-term catalyst. In the next 1–3 months, watch for bid terms, evaluation criteria and award timing. A win would validate UK public-sector access, but a loss would be more informative about competitive displacement than the settlement itself.

The larger second-order exposure is reputational contagion across UK public contracts: the police tender and the NHS data contract are separate decisions, yet opposition to Palantir can raise scrutiny, lengthen procurement timelines and increase customers’ perceived implementation risk. That could advantage less politically exposed bidders even without a demonstrated technical edge. Conversely, the joint statement makes values-based exclusion harder to defend in this specific procurement; it does not establish a general legal shield for future awards.

Contrarian view: the headline resolution may look like a de-risking event, but the commercially relevant outcome is still undecided and the NHS renewal remains a distinct overhang. Avoid inferring a durable UK demand recovery from withdrawal of claims. Falsifiers: a confirmed police award and continued NHS contract support would weaken the risk case; a tender exclusion, delayed award, or credible NHS replacement plan would strengthen it. No valuation, position sizing, or market-implied expectations are provided, so a directional trade is not justified on this item alone.

Key Decisions for Investors

• Do not initiate a standalone PLTR trade on the settlement; it removes legal uncertainty without securing revenue.
• Set an event watch for the police tender: verify award criteria, timing, competing bids and final contract scope before reassessing PLTR’s UK public-sector outlook.
• Track the NHS contract separately for renewal milestones, procurement signals and evidence of a replacement process; treat public opposition as a timeline and execution risk, not proof of cancellation.
• Revisit a bearish view if the police bid is excluded or the NHS contract faces a credible replacement path; revisit a bullish view only after a confirmed award and evidence that implementation proceeds.